Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29456981 | 1.00 | KMT2A (0.35) | KMT2AMEN1KDM4ELMNAPOLB | |
| SCHEMBL9846168 | 0.87 | KMT2A (0.33) | KMT2AMEN1KDM4ELMNAPOLB | |
| SCHEMBL9681878 | 0.87 | KMT2A (0.35) | KMT2AMEN1KDM4ELMNAPOLB | |
| SCHEMBL9846239 | 0.84 | MEN1 (0.32) | KMT2AMEN1ALDH1A1HPGDRAB9A | |
| L-697661 SCHEMBL599639 | 0.84 | FABP4 (0.34) | KMT2AMEN1KDM4EALDH1A1HPGD | |
| L-697661 SCHEMBL29456987 | 0.84 | FABP4 (0.34) | KMT2AMEN1KDM4EALDH1A1HPGD | |
| SCHEMBL9170726 | 0.84 | PIK3CD (0.42) | ELANE | |
| SCHEMBL9681377 | 0.83 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL9171193 | 0.81 | FABP4 (0.34) | — | |
| SCHEMBL9283877 | 0.80 | ALDH1A1 (0.39) | KMT2AMEN1KDM4ELMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| EP-0666744-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1995-08-16 | — | — | EP | claimed |
| WO-1994009781-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1994-05-11 | — | — | WO | claimed |
| EP-0577243-A2 | Recombinant human HIV-neutralizing monoclonal antibodies for prevention and treatment of HIV infection | MERCK & CO. INC. (US) | 1994-01-05 | — | — | EP | claimed |
| WO-1993019785-A1 | RECOMBINANT HUMAN HIV-NEUTRALIZING MONOCLONAL ANTIBODIES FOR PREVENTION AND TREATMENT OF HIV INFECTION | MERCK & CO., INC. (US) | 1993-10-14 | — | — | WO | claimed |
| EP-0484071-A2 | Synergism of HIV reverse transcriptase inhibitors | MERCK & CO. INC. (US) | 1992-05-06 | — | — | EP | claimed |
| EP-0462800-A2 | Inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | claimed |
| JP-4300834-A | — | — | None | — | — | JP | disclosed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
| EP-0666744-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1995-08-16 | — | — | EP | disclosed |
| WO-1994009781-A1 | USE OF BHAP COMPOUNDS IN COMBINATION WITH OTHER NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR THE TREATMENT OF HIV INFECTION | THE UPJOHN COMPANY (US) | 1994-05-11 | — | — | WO | disclosed |
| WO-1993019785-A1 | RECOMBINANT HUMAN HIV-NEUTRALIZING MONOCLONAL ANTIBODIES FOR PREVENTION AND TREATMENT OF HIV INFECTION | MERCK & CO., INC. (US) | 1993-10-14 | — | — | WO | disclosed |
| US-5215900-A | Biosynthesis a culture product utilizing as enzyme inhibitor in treatment of immune deficiency syndrome | MERCK & CO., INC. (US) | 1993-06-01 | — | — | US | disclosed |
| US-5169769-A | Aerobic culture product | MERCK & CO., INC. (US) | 1992-12-08 | — | — | US | disclosed |
| JP-H04300834-A | SYNERGISM OF HIV REVERSE TRANSCRIPTASE INHIBITOR | MERCK & CO INC | 1992-10-23 | — | — | JP | disclosed |
| EP-0484071-A2 | Synergism of HIV reverse transcriptase inhibitors | MERCK & CO. INC. (US) | 1992-05-06 | — | — | EP | disclosed |
| EP-0462808-A2 | Inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| EP-0462800-A2 | Inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | KMT2A 3265/4885MEN1 4840/4885KDM4E 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.